Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03895684 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Salarius Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT03895684: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Salarius Pharmaceuticals.
NCT03895684 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Salarius Pharmaceuticals. The registered enrollment target is 23 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03895684, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Salarius Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
Primary Outcome
Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
Conditions Studied
Interventions
- DRUG SP-2577 Seclidemstat
Study Locations (2)
Arizona
- HonorHealth - Scottsdale
California
- Sarcoma Oncology Research Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2021-04-13 |
| Phase | Phase 1 |
What the finished NCT03895684 record still lists
NCT03895684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SP-2577 Seclidemstat is the first listed.
NCT03895684 reports a single indexed study location in Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03895684 about?
NCT03895684 is a clinical study titled "Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors". Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
What is the current status of trial NCT03895684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-06-25. Estimated completion is 2021-04-13.
What conditions does trial NCT03895684 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT03895684?
The interventions under investigation include: SP-2577 Seclidemstat (DRUG).
Who is sponsoring clinical trial NCT03895684?
This trial is sponsored by Salarius Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03895684 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03895684's enrollment target sits among peer trials
23 125th of 144 higher than 20 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI